Why Regulatory Agencies Disagree on New Alzheimer’s Treatments

Regulatory agencies are currently divided over the approval and deployment of new monoclonal antibody treatments for Alzheimer’s disease, creating a global disparity in patient access to these therapies. A report by Nayanah Siva in The Lancet on May 30, 2026, examines why different health authorities have reached conflicting conclusions regarding the risk-benefit profiles of these drugs.

The controversy centers on a class of drugs designed to clear amyloid-beta plaques from the brain, which are a hallmark of Alzheimer’s pathology. While some regulators have granted approval based on the drugs’ ability to slow cognitive decline, others argue that the clinical benefit is too modest to justify the associated safety risks.

Divergent Regulatory Standards

The United States Food and Drug Administration (FDA) has historically taken a more permissive approach toward these treatments. The FDA approved lecanemab on July 6, 2023, utilizing a framework that prioritizes the slowing of disease progression, even if the absolute improvement in daily functioning is perceived as small by some clinicians.

In contrast, the European Medicines Agency (EMA) has maintained a more cautious stance. The EMA’s assessments have frequently highlighted a lack of sufficient evidence that the reduction of amyloid plaques translates into a clinically meaningful benefit for the patient’s quality of life.

This regulatory split stems from different interpretations of trial data. One agency may view a 27 percent slowing of cognitive decline over 18 months as a significant victory for a terminal condition, while another may view the same figure as an insufficient margin of improvement when weighed against severe side effects.

The Risk of ARIA

The primary safety concern driving these differing assessments is Amyloid-Related Imaging Abnormalities, known as ARIA. This condition manifests as brain swelling (ARIA-E) or small brain bleeds (ARIA-H), which are detected via MRI scans.

While many cases of ARIA are asymptomatic, some patients experience severe complications, including seizures, cognitive worsening, or death. The frequency and severity of these events vary depending on the patient’s genetic profile, particularly those who carry the APOE ε4 allele.

Regulators in Europe have expressed greater concern that the infrastructure required to safely monitor patients—including frequent and expensive MRI imaging—is not universally available, potentially increasing the risk of undetected and untreated ARIA.

The Amyloid Hypothesis Debate

The disagreement among agencies also reflects a broader scientific debate over the amyloid hypothesis. This theory suggests that the accumulation of amyloid-beta is the primary cause of Alzheimer’s and that removing it will stop or reverse the disease.

Critics of the amyloid-centric approach argue that removing plaques does not necessarily address the underlying neurodegeneration or tau protein tangles that more closely correlate with cognitive loss. This scientific uncertainty makes it difficult for regulators to agree on a universal standard for success.

the threshold for what constitutes a successful drug varies by region. Some authorities require proof of a significant restoration of function, while others accept a slowing of the rate of decline as a sufficient endpoint for approval.

Clinical Implications and Future Outlook

The lack of international consensus creates a fragmented landscape for clinicians and patients. In some jurisdictions, patients can access these therapies through insurance or government funding, while in others, the drugs remain unavailable or are restricted to clinical trial settings.

Medical professionals are now calling for more standardized global metrics to evaluate Alzheimer’s treatments. These metrics would ideally combine cognitive test scores with real-world functional assessments to determine if a drug actually improves a patient’s ability to perform daily tasks.

Ongoing research is shifting toward combination therapies that target both amyloid and tau proteins, as well as inflammation in the brain. These next-generation treatments may eventually provide the clearer evidence of efficacy needed to align global regulatory assessments.